BPC-157 vs TB-500

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 6 references

BPC-157 and TB-500 are different molecules: BPC-157 is a 15-residue peptide, and TB-500 is a seven-residue fragment of Thymosin Beta-4.

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

BPC-157 · 15 residues

TB-500 · 7 residues

Ac: N-terminal acetyl group. Letters are one-letter amino acid codes.

Chain length
BPC-15715 residues
TB-5007 residues
Molecular weight
BPC-1571,419.55 g/mol
TB-500889.02 g/mol

Drawn from the product database. Each measure's bars share one scale.

BPC-157 vs TB-500, compared
What it isA synthetic 15-residue peptide. Described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1]A synthetic seven-residue peptide corresponding to residues 17 to 23 of Thymosin Beta-4.
How they relateDifferent molecules from different parents. BPC-157 is described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1] TB-500 corresponds to residues 17 to 23 of Thymosin Beta-4.
CAS number137525-51-0885340-08-9
Molecular formulaC62H98N16O22C38H68N10O14
Molecular weight1,419.55 g/mol889.02 g/mol
SequenceGEPPPGKPADDAGLVAc-LKKTETQ
Evidence baseNearly all published research is preclinical. A 2025 systematic review counted 36 studies within its scope; the one clinical study was a retrospective case series of 12 patients. No randomized controlled trial has been published within that scope.Cell-culture and explant assays tested a peptide with its seven-residue sequence.[2] An aged-mouse study tested a synthetic peptide with that sequence.[3] Attributed activity not directly determined with TB-500 itself in animal or human studies, in the literature reviewed for it.
Regulatory statusThe FDA has not approved BPC-157 for human use.The FDA has not approved TB-500 for human use.
Compared head-to-head?Not with this form: a 2026 rat study tested BPC-157 and a product it calls TB-500, without giving that product's sequence.[4] No comparison of BPC-157 with a preparation identified as TB-500's seven-residue fragment found in PubMed (searched October 2026).[5]
Handling differenceNeither contains a cysteine, a methionine or an aromatic residue. In solution, BPC-157's adjacent aspartates can rearrange, and TB-500's C-terminal glutamine can deamidate.

How BPC-157 and TB-500 differ

BPC-157 and TB-500 are different molecules with different parents. BPC-157 is a 15-residue peptide, described in the originating literature as a partial sequence of a protein reported in human gastric juice.[1] It does not occur in nature in that isolated form, and the material used in studies is produced synthetically. TB-500 is a synthetic seven-residue peptide. At their N-terminal ends, BPC-157 has a free amine and TB-500 carries an acetyl group.

TB-500 corresponds to residues 17 to 23 of Thymosin Beta-4, and in the literature reviewed for TB-500, most studies used the full-length parent rather than a peptide with TB-500's sequence. Much of that foundational work comes from a relatively small number of groups. The literature reviewed for TB-500 reports no human safety data. A small number of affiliated laboratories produced much of the foundational animal work on BPC-157.

A 2025 systematic review found that the BPC-157 evidence base within its scope remains overwhelmingly preclinical.[6] Within that review's scope, the one clinical study was a retrospective case series of 12 patients, and no randomized controlled trial has been published. In the literature reviewed for BPC-157, human safety data are sparse. In the literature reviewed for TB-500, the activity attributed to it has not been directly determined with TB-500 itself in animal or human studies.

Have BPC-157 and TB-500 been compared directly?

A 2026 study tested BPC-157 and a product it calls TB-500, each in its own group, in a rat model.[4] The paper describes that product as a synthetic peptide derived from Thymosin Beta-4 but gives no sequence for it, so it does not establish which compound was tested.[4] Results are reported for each compound in that model. No comparison of BPC-157 with a preparation identified as TB-500's seven-residue fragment found in PubMed (searched October 2026).[5] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is BPC-157 the same as TB-500?+

BPC-157 and TB-500 are different molecules: BPC-157 is a 15-residue peptide, and TB-500 is a seven-residue fragment of Thymosin Beta-4. BPC-157 is described in the originating literature as a partial sequence of a protein reported in human gastric juice.

References

  1. 1
    Rat study, 1994. PMID 7904712.
  2. 2
    Cell-culture and explant study, 2003. PMID 14500546.
  3. 3
    Mouse study, 2003. PMID 12581423.
  4. 4
    Biçer O, et al. 2026. PMID 42542926.
  5. 5

    PubMed search, 3 October 2026 (records to 2 October 2026)

    10 records; none was a direct comparison of BPC-157 with a preparation identified as TB-500's seven-residue fragment.

    Exact query (NCBI E-utilities): ("BPC-157"[tiab] OR "BPC 157"[tiab] OR "BPC157"[tiab] OR "body protection compound"[tiab] OR "gastric pentadecapeptide"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR "TB500"[tiab] OR "TB 500"[tiab] OR "LKKTETQ"[tiab] OR "Ac-LKKTETQ"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  6. 6
    Vasireddi N, et al. 2025. PMID 40756949.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

BPC-157 vs KPV

BPC-157 is a 15-residue peptide and KPV a three-residue peptide corresponding to residues 11 to 13 of alpha-MSH: two different molecules.

Read Comparison
Comparison

BPC-157 vs Thymosin Beta-4

BPC-157 is a 15-residue peptide and Thymosin Beta-4 a 43-residue member of the beta-thymosin family: two different molecules.

Read Comparison
Comparison

TB-500 vs Thymosin Alpha-1

TB-500 is a seven-residue fragment of Thymosin Beta-4 and Thymosin Alpha-1 a separate 28-residue peptide: two different molecules.

Read Comparison